Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 483-490

  Bishara, Delia ^a   Taylor, David ^a,b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Asenapine; Bipolar I disorder; Schizophrenia

Indexed keywords

EID: 70449702359     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. NeuroRx. 2006;3(1):10-21. (Pubitemid 43276632)
2. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1159-1172. (Pubitemid 37464960)
3. Rowley M, Bristow LJ, Hutson PH. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001;44(4):477-501. (Pubitemid 32156091)
4. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. (Pubitemid 30191189)
5. Gervin M, Barnes TRE. Assessment of drug-related movement disorders in schizophrenia. Adv Psychiatr Treat. 2000;6:332-341.
6. Cavallaro R, Smeraldi E. Antipsychotic-induced tardive dyskinesia. Recognition, prevention and management. CNS Drugs. 1995;4(4):278-293.
7. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314. (Pubitemid 39388605)
8. Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol. 2000;20(3):295-304. (Pubitemid 30318357)
9. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111-123. (Pubitemid 26050500)
10. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835.
11. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl). 2002;162(1):11-17.
12. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159(6):1018- 1028. (Pubitemid 34586949)
13. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51-68. (Pubitemid 29023554)
14. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Health Technology Appraisal No. 43;2002. URL http://www.nice.org.uk. 2002.
15. Ashby CR Jr, Wang RY. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse. 1996;24(4):349-394.
16. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91. (Pubitemid 36070868)
17. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796. (Pubitemid 18222922)
18. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274-285.
19. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl). 1989;99 Suppl:S47-S53. (Pubitemid 19244139)
20. Atkin K, Kendall F, Gould D, Freeman H, Lieberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169:483-488. (Pubitemid 126735804)
21. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-246. (Pubitemid 19261970)
22. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11):873-883. (Pubitemid 34020700)
23. Westerink BH. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol. 2002;455(1):1-18.
24. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35(6):205-219. (Pubitemid 36061310)
25. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002;63 Suppl 9:25-29.
26. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251-267. (Pubitemid 38393435)
27. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry. 2001;62(11):841-842.
28. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published erratum: Arch Gen Psychiatry. 2004;61:176]. Arch Gen Psychiatry. 2003;60(11):1079-1088.
29. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. (Pubitemid 40905587)
30. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-2312.
31. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-48. (Pubitemid 40934073)
32. Cookson J. Atypical antipsychotics in bipolar disorder: the treatment of mania. Adv Psychiatr Treat. 2008;14(5):330-338.
33. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
34. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989;99 Suppl:S18-S27.
35. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(2 Suppl):106S-115S.
36. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl). 2004;174(1):17-24.
37. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl). 2008;198(1):103-111.
38. Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology. 2008;33(12):2934-2945.
39. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol. 2005;15(2):143-151. (Pubitemid 40193419)
40. Neale AC, Jenkins H, Amend D, Lesen M. A 14 day dose escalation, double-blind, randomized, placebo-controlled study of SB518 in adult patients with schizophrenia [abstract]. Neuropsychopharmacology. 2005;30 Suppl 1:S54.
41. Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci. 2004;25(9):481-486.
42. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1145-1158.
43. Ghanbari R, El MM, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol. 2009;19(3):177-187.
44. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005;10(13):917-925.
45. Marston HM, Young JW, Martin FD, et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl). 2009.
46. Jentsch JD, Shahid M, Wong E, Roth RH. Asenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine. Schizophr Res. 2006;81:85.
47. Tarazi FI, Choi YK, Gardner M, Wong EH, Henry B, Shahid M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse. 2009;63(5):413-420.
48. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets. Diabetes. 2005;54(5):1552-1558.
49. Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008;196(3):417-429. (Pubitemid 351200428)
50. Peeters P, de Greef R, Hulskotte E, et al. Asenapine: an overview of phase I pharmacokinetic studies. 2009. Paris, France, Poster presented at 9th World Congress of Biological Psychiatry, 28 June-2 July 2009.
51. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-1500. (Pubitemid 350073395)
52. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
53. Guy W. The Clinical Global Impressions Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology Rev Ed. Rockville, MD: National Institute of Mental Health, 1976:157-169.
54. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25-40. (Pubitemid 23030357)
55. Emsley R, Doelder PD, Schoemaker J, Naber D. Long-term safety of asenapine in patients with schizophrenia. Schizophr Res. 2008;98 Suppl 1:48.
56. Preskorn S, Chapel S, Panagides J. Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia. Eur Neuropsychopharmacol. 2007;17 Suppl 4:S453.
57. Fleming K, Potkin SG, Binneman B, Keller D, Alphs L, Panagides J. Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Eur Neuropsychopharmacol. 2007;17 Suppl 4:S466.
58. McIntyre R, Hirschfeld R, Alphs L, Cohen M, Macek T, Panagides J. Randomized and placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorder. Schizophr Res. 2008;98 Suppl 1:5-6.
59. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. (Pubitemid 9006756)
60. McIntyre R, Alphs L, Cohen M, Keller DS, Macek T, Panagides J. Long-term double-blind extention studies of asenapine vs. olanzapine in patients with bipolar mania. Schizophr Res. 2008;98 Suppl 1:48.
61. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines, 10th Edn. London, UK: Informa Healthcare; 2009.